CA-NETAPP
26.6.2024 14:01:30 CEST | Business Wire | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that NetApp ONTAP® Autonomous Ransomware Protection with Artificial Intelligence (ARP/AI) has received a AAA rating from SE Labs, an independently-owned and run testing company that assesses security products and services. SE Labs validated the protection effectiveness of NetApp ARP/AI with 99 percent recall—a metric that measures malware detection rates—for ransomware attacks, while noting the absence of false positives.
When responding to ransomware attacks, seconds can make the difference between ensuring continuity and a massive business disruption. Organizations need fast, automated, and accurate detection and response capabilities built into their primary storage systems to minimize the damage done by lost production data and downtime. NetApp ARP/AI, with its AI-powered ransomware detection capability, addresses this gap by providing real-time detection and response to minimize the impact of cybersecurity threats.
SE Labs rigorously tested NetApp ARP/AI against hundreds of known ransomware variants with impressive results. NetApp ARP/AI demonstrated 99 percent detection of advanced ransomware attacks. NetApp ARP/AI also achieved 100 percent detection of legitimate files without flagging any false positives, indicating a strong ability to operate in a business context without contributing to alert fatigue.
Ensuring data is secure against internal and external threats is a critical part of making data infrastructure intelligent which then empowers customers to turn disruption into opportunity. This validation of NetApp’s AI-powered ransomware detection capabilities underscores how NetApp is staying at the forefront of AI innovation by both enabling AI adoption and applying AI to data services. NetApp’s newly released more powerful, all-flash storage systems help enterprises leverage their data to drive AI workloads, built on NetApp’s secure storage infrastructure.
"NetApp has passed a significant milestone in the fight against ransomware as the first and only storage vendor to offer AI-driven on-box ransomware detection with externally validated top-notch protection effectiveness,” said Dr. Arun Gururajan, Vice President, Research & Data Science at NetApp. “Ransomware detection methodologies that rely only on backup data are too slow to effectively mitigate the risks businesses face from cybersecurity threats. NetApp ARP/AI hardens enterprise storage by providing robust, built-in detection capabilities that can respond to ransomware threats in real time. The AAA rating we achieved from SE Labs is the result of our commitment to innovation in intelligent data infrastructure and our drive to find new ways to make NetApp the most secure storage on the planet.”
By embedding ransomware detection in storage, NetApp ARP/AI helps customers improve their cyber resilience while reducing the operational burden and skills required to maintain their intelligent data infrastructure. NetApp ARP/AI’s detection technology continuously adapts and evolves as new ransomware variants are discovered. This continuous retraining on the latest ransomware strains ensures that NetApp ARP/AI remains at the forefront of protection effectiveness, offering organizations a future-proof defense against the dynamic ransomware landscape.
To see the full results of the tests, read the SE Labs Report.
NetApp ARP/AI is currently in tech preview. Customers can request to participate in the tech preview by reaching out to their NetApp sales representative.
Additional Resources
- NetApp, the First and Leading AI-Powered Autonomous Ransomware Protection Native to Storage Achieves Remarkable AAA Rating and 99% Detection Accuracy and 100% Legitimate Accuracy in SE Labs Validation Testing
- Protect, Detect, Recover; Guaranteed
About NetApp
NetApp is the intelligent data infrastructure company, combining unified data storage, integrated data services, and CloudOps solutions to turn a world of disruption into opportunity for every customer. NetApp creates silo-free infrastructure, harnessing observability and AI to enable the industry’s best data management. As the only enterprise-grade storage service natively embedded in the world’s biggest clouds, our data storage delivers seamless flexibility. In addition, our data services create a data advantage through superior cyber resilience, governance, and application agility. Our CloudOps solutions provide continuous optimization of performance and efficiency through observability and AI. No matter the data type, workload, or environment, with NetApp you can transform your data infrastructure to realize your business possibilities. Learn more at www.netapp.com or follow us on X, LinkedIn, Facebook, and Instagram.
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240626446291/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom